Tue, Jul 15, 2025 11:00 AM EDT
Get actionable insights into accelerated drug product development, optimized manufacturing processes for viscosities ≤50 cP, and commercial viability for next-generation biologics.
Register Free: https://www.biopharminternational.com/bp_w/device-capability
Event Overview:
The biopharmaceutical industry’s shift toward patient-centric, high-dose therapies, which is based on a growing demand for subcutaneous (SC) administration, requires innovative approaches to overcome technical barriers. This webinar discusses 3 integrated strategies to achieve high-dose delivery:
Attendees can expect actionable insights into accelerated drug product development, optimized manufacturing processes for viscosities ≤50 cP, and commercial viability for next-generation biologics.
Key Learning Objectives:
Who Should Attend:
Featured Speaker:
Jeremy Guo, PhD
Senior Vice President and Head of
Drug Product Development and Clinical Drug Product Manufacturing
WuXi Biologics
Jeremy Guo, PhD, is senior vice president and the head of drug product development and clinical drug product manufacturing at WuXi Biologics. He has over 20 years of industry experience in formulation, process, and device development for biologics covering a wide range of modalities, including recombinant proteins, at Amgen, Regeneron, and Pfizer. Guo received his PhD from the University of Utah and his BS from the University of Colorado.
Dr. Guo led his team to equip global partners with preclinical, clinical, and commercial drug product development and manufacturing for a wide range of modalities, including monoclonal antibodies, bispecific antibodies, Fc-fusion proteins, recombinant proteins, and enzymes. They also develop special preparations, such as high-concentration protein preparations, coprescription preparations, peptide preparations, nanoparticle preparations, and vaccines.
Speaker's Email: jeremy_guo@wuxibiologics.com
Speaker's LinkedIn: https://www.linkedin.com/in/jeremy-guo-0164821/
Register Free: https://www.biopharminternational.com/bp_w/device-capability
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.